Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy hair loss is usually temporary telogen effluvium caused by rapid weight loss, nutrient shifts, and metabolic changes. Shedding typically peaks between months 4-6 and regrowth occurs by months 7-12. Effective management includes optimizing nutrition (protein, iron, zinc, biotin), gentle hair care, stress reduction, and consistent monitoring. Medication changes should only follow a benefit-risk conversation with your provider.
Key considerations include recognizing warning signs, understanding recovery timelines, knowing when to seek immediate medical advice, and evaluating alternative therapies.
If you're experiencing hair shedding on Wegovy, it's important to determine whether it's typical telogen effluvium or a sign of something more serious like nutrient deficiency, thyroid dysfunction, or another underlying condition. A free, instant, online symptom check can help you evaluate your symptoms in minutes, understand possible causes, and guide your next steps—whether that's adjusting your routine or scheduling a provider visit.
Reviewed for medical accuracy: 07/10/2026
Wegovy (semaglutide) has become a game-changer for many people seeking sustainable weight loss. Yet some users report hair thinning or shedding. If you're asking "why does Wegovy cause hair loss," you're not alone. Understanding the science, expected timelines, management strategies and when to consider switching medications can help you make a safe, informed choice.
Clinical studies list hair loss (alopecia) as a less common adverse event (occurring in fewer than 1% of participants). Yet real-world experience suggests telogen effluvium—a temporary, diffuse shedding—can arise in a subset of patients.
Hair growth follows a cycle with three phases:
Factors that abruptly push hairs into the telogen phase can trigger telogen effluvium. Wegovy may contribute to hair shedding through:
By understanding these mechanisms, it becomes clear that hair loss with Wegovy often reflects a transient response to metabolic shifts rather than direct toxicity.
Watch for:
Most cases of Wegovy-associated hair loss resolve without stopping the drug. Consider these steps:
Deciding whether to switch off Wegovy depends on balancing the drug's benefits—significant weight reduction and metabolic improvements—against the distress of hair thinning. Consider:
Important: Never stop or change medications on your own. Always discuss switching, dose changes or new therapies with your doctor.
While Wegovy-related hair loss is not life-threatening, certain symptoms warrant prompt evaluation:
If you're noticing unusual symptoms or feeling unsure about what's happening with your body, take a few minutes to check your symptoms with Ubie's free AI-powered symptom checker—it can help you better understand your situation and guide you toward the right level of care.
Your journey to better health should include both physical milestones and emotional well-being. If hair loss becomes distressing or if you notice additional troubling symptoms, don't hesitate to seek professional advice. Remember, your doctor is your best resource for personalized recommendations—and taking early action can help you stay on track with both your weight-loss and wellness goals.
(References)
* Li Z, Deng H, Zheng Q, et al. Hair loss with GLP-1 receptor agonists: a systematic review. J Cosmet Dermatol. 2024 Mar;23(3):1052-1060. doi: 10.1111/jocd.16113. Epub 2024 Feb 5. PMID: 38317585.
* Patel J, Awan R, Agrawal M, et al. Hair Loss Associated with GLP-1 Agonists: A Review of Clinical Trials and Postmarketing Data. Dermatol Pract Concept. 2024 Jan 31;14(1):e2024040. doi: 10.5826/dpc.1401a40. PMID: 38329622; PMCID: PMC10842211.
* Meiboom AC, O'Connell KA, Kollipara R, et al. Semaglutide-associated telogen effluvium: A case series. J Am Acad Dermatol. 2023 Sep;89(3):e69-e70. doi: 10.1016/j.jaad.2023.05.021. Epub 2023 Jun 2. PMID: 37271424.
* Zhang M, Zhang B, Shi H, et al. Adverse Events Associated with Semaglutide: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS). Front Pharmacol. 2022 Oct 11;13:995166. doi: 10.3389/fphar.2022.995166. PMID: 36304419; PMCID: PMC9603091.
* Malkud S. Telogen Effluvium: A Review of the Triggers. J Clin Diagn Res. 2015 Aug;9(8):WE01-3. doi: 10.7860/JCDR/2015/15219.6210. Epub 2015 Aug 1. PMID: 26557555; PMCID: PMC4629916.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.